Novartis (NYSE:NVS) announced that its Phase III GCAptAIN study of Cosentyx® (secukinumab) in giant cell arteritis (GCA) did not meet its primary endpoint of sustained remission at Week 52. The study evaluated Cosentyx in combination with a 26-week steroid taper versus placebo with a 52-week steroid taper in adults with newly diagnosed or relapsing GCA.
While secondary outcomes showed numerically better results for cumulative steroid dose and steroid-related toxicity compared to placebo, they did not achieve statistical superiority. The safety profile remained consistent with Cosentyx's known safety data across approved indications. Novartis plans to conduct a full evaluation of the study data and share detailed results in the future.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.